1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Getinge AB
  6. News
  7. Summary
    GETI B   SE0000202624

GETINGE AB

(GETI B)
  Report
Delayed Nasdaq Stockholm  -  05/24 11:29:56 am EDT
279.10 SEK    0.00%
04/27Getinge To Buy France's FLUOPTICS in $27.4 Million Deal
MT
04/27GETINGE : to acquire FLUOPTICS, a technology leader in the area of Near Infrared Imaging
PU
04/27GETINGE AB : Ex-dividend day for final dividend
FA
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Getinge appoints Elin Frostehav as President Acute Care Therapies and Eric Honroth as President Life Science

01/17/2022 | 09:00am EDT

Getinge appoints new Presidents for two business areas and members of the Executive team. Elin Frostehav is appointed President Acute Care Therapies and Eric Honroth President Life Science starting April 1, 2022.

Elin Frostehav has been appointed President Acute Care Therapies and member of the Getinge Executive team. Elin currently serves as Vice President Critical Care, a product area within Acute Care Therapies in Getinge. Elin joined Getinge in 2019 and has previously held leading global positions within Semcon, an international technology company, in the areas of product development and digitalization. Prior to Semcon Elin held various positions at FlexLink, a global factory automation company. Elin succeeds Jens Viebke who will take on a new role in Getinge as Executive Vice President Research & Business Development, focusing on Getinge's Research Programs and M&A activities. In this role, Jens Viebke will continue to report to Mattias Perjos, President & CEO. He will not be a member of the Executive Team.

Eric Honroth has been appointed President Life Science and member of the Getinge Executive team. Eric is currently President North America Region in Getinge and has been with the company since 2018. He has more than 20 years of extensive experience in global leadership roles in the medical devices industry such as Becton Dickinson, CareFusion and Abbott Vascular. Eric succeeds Harald Castler who after a long and successful career in Getinge has decided to retire.

All changes are effective as of April 1, 2022.


Media contact
Anna Appelqvist, VP Corporate Communications
Phone: +46 734 244 527
Email: anna.appelqvist@getinge.com

About Getinge
With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions aiming to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs over 10,000 people worldwide and the products are sold in more than 135 countries.

https://news.cision.com/getinge/r/getinge-appoints-elin-frostehav-as-president-acute-care-therapies-and-eric-honroth-as-president-life,c3487122

https://mb.cision.com/Main/942/3487122/1521274.pdf

https://news.cision.com/getinge/i/elin-frostehav,c3000643

https://news.cision.com/getinge/i/eric-honroth--getinge,c3000644

(c) 2022 Cision. All rights reserved., source Press Releases - English

All news about GETINGE AB
04/27Getinge To Buy France's FLUOPTICS in $27.4 Million Deal
MT
04/27GETINGE : to acquire FLUOPTICS, a technology leader in the area of Near Infrared Imaging
PU
04/27GETINGE AB : Ex-dividend day for final dividend
FA
04/26Resolutions at Getinge's Annual General Meeting 26 April 2022
AQ
04/26Getinge AB Declares Dividend for 2021, Payable on May 3, 2022
CI
04/26European stocks slide with eyes on U.S. tech earnings
RE
04/26TRANSCRIPT : Getinge AB, Q1 2022 Earnings Call, Apr 26, 2022
CI
04/26GETINGE : Presentation Q1 2022 Report
PU
04/26Medical gear maker Getinge's profit falls on supply chain trouble
RE
04/26Medical gear maker Getinge's profit falls on supply chain trouble
RE
More news
Analyst Recommendations on GETINGE AB
More recommendations
Financials
Sales 2022 29 546 M 3 020 M 3 020 M
Net income 2022 3 563 M 364 M 364 M
Net Debt 2022 2 216 M 226 M 226 M
P/E ratio 2022 21,4x
Yield 2022 1,63%
Capitalization 76 018 M 7 769 M 7 769 M
EV / Sales 2022 2,65x
EV / Sales 2023 2,40x
Nbr of Employees 10 892
Free-Float 79,8%
Chart GETINGE AB
Duration : Period :
Getinge AB Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GETINGE AB
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 279,10 SEK
Average target price 415,67 SEK
Spread / Average Target 48,9%
EPS Revisions
Managers and Directors
Mattias Sven Perjos President, Chief Executive Officer & Director
Lars Sandstr÷m Chief Financial Officer
Johan Malmquist Chairman
Anna Romberg Executive VP-Legal, Compliance & Governance
Johan Bygge Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GETINGE AB-29.36%7 739
NOVOCURE LIMITED-1.98%8 061
MASIMO CORPORATION-51.68%7 899
SHOCKWAVE MEDICAL, INC.-9.89%5 926
PENUMBRA, INC.-51.26%5 369
ASAHI INTECC CO., LTD.-19.30%4 240